This antibody recognizes the N-teminus of CD195, an approximately 45 kDa G-protein coupled receptor 1 family protein expressed on resting T cells, monocytes, macrophages, and immature dendritic cells.

Applicazioni

Flow Cytometry, IP, WB, ICC, ELISA

Diluizioni consigliate

WB: Do not boil cell lysates prior to SDS-PAGE, Flow Cytometry: 1-4 µg/ml.

Reattività

Human

Immunogeno

CCR5 peptide (Met1-Lys22) KLH conjugate.

Specie ospite

Mouse

Clonalità

Monoclonal

Clona ID

T21/8

Isotipo

IgG1

Catene leggere

kappa

Coniugare

Unconjugated

Purificazione

Protein A chromatography.

Concentrazione

1 mg/ml

MW previsto

45 kDa

Forma del prodotto

Liquid

Formulazione

Supplied in Phosphate Buffered Saline, pH 7.4, with 15 mM Sodium Azide.

Conservazione

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze/thaw cycles.

Sinonimi

AM4 7, C C chemokine receptor type 5, C C CKR 5, C-C chemokine receptor type 5, C-C CKR-5, C-C motif chemokine receptor 5 A159A, CC Chemokine Receptor 5, CC Chemokine Receptor Type 5, CC CKR 5, CC-CKR-5, CCCKR 5, CCCKR5, CCR 5, CCR-5, CCR5 chemokine (C C motif) receptor 5, CCR5_HUMAN, CD 195, CD195, CD195 Antigen, Chemokine C C motif receptor 5, Chemokine receptor CCR5, CHEMR13, CKR 5, CKR5, CMKBR 5, CMKBR5, FLJ78003, HIV 1 Fusion Coreceptor, HIV-1 fusion coreceptor, HIV1 fusion coreceptor, IDDM22, MIP-1 alpha receptor

Controlli isotipo

Secondari adatti

Dichiarazione di non responsabilità

Questo prodotto è solo per uso di ricerca. Non è inteso per uso diagnostico o terapeutico.

Pubblicazioni per questo clone (1)

Clicca sull'immagine per la visualizzazione estesa

Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells

Riferimenti: Anti-CCR5 Antibody [T21/8] (ab110103)

Astratto:

Previous studies have investigated the mechanisms of immune evasion of tumor cells in numerous types of advanced solid malignant tumor, and several types of immune preparations have been administered as antitumor adjuvant therapies. However, in the majority of studies, the efficacy of therapies has been revealed to be limited. The present study aimed to investigate the immune evasion mechanisms employed by early colorectal cancer cells and the expression of the molecules associated with immune evasion during the malignant transformation process of normal colorectal epithelial cells to measure the effects of immune intervention for early colorectal cancer, and to improve the efficacy of immunotherapy. A total of 60 colorectal tissues, including 15 normal mucosa, 15 adenoma, 15 early cancer and 15 advanced cancer tissues, from patients undergoing endoscopic procedures in Huadong Hospital Affiliated to Fudan University (Shanghai, China) were collected. A comparison of baseline characteristics among these four groups was performed. The expression levels of human leukocyte antigen-A (HLA-A), apoptosis antigen 1 (Fas), c-c chemokine receptor type 5 (CCR5), Fas ligand (FasL) and HLA-E in each group were detected by immunohistochemical analysis. Furthermore, 15 patients with advanced colorectal cancer were enrolled into the present study. Advanced cancer and paracancer tissues (normal mucosal tissues 3 cm away from the margin of cancer tissues) were collected from each patient by colonoscopic biopsy. The expression levels of HLA-A, Fas, CCR5, FasL and HLA-E in each group were detected by western blot analysis. During the malignant transformation process of normal colorectal epithelial cells, the expression levels of CCR5, FasL and HLA-E increased significantly (P<0.001), whilst the expression levels of Fas reduced significantly (P=0.0271). In the early cancer group, the expression levels of Fas reduced significantly (P=0.0239), whilst the expression levels of HLA-E increased significantly (P<0.001) compared with adenoma group. In conclusion, a loss of Fas expression and high expression levels of HLA-E may promote the immune evasion of early colorectal cancer cells.

Visualizza pubblicazione